Laurus Labs Ltd. News and Updates

Name: Latest research reports of Laurus Labs Ltd. authored by KRChoksey and published by - Trendlyne research reports.
Item: Laurus Labs Ltd.
Rating: 4
Author: KRChoksey

Keep track of all breaking news on Laurus Labs Ltd. from all sources in a single place.

Laurus Labs Ltd.

30 Apr 2025

620.55

2.77%

Strong execution with positive Custom Synthesis outlook

Accumulate: Laurus Labs Ltd.

KRChoksey

Laurus Labs’ revenue for Q4FY25 stood at INR 17,203 Mn., up 19.5% YoY (+21.6% QoQ), which was above our estimates led by strong growth in Custom Synthesis segment.
Adj. EBITDA came in at INR 4,206 Mn., up 74.2% YoY (+47.5% QoQ), led by margin improvement of 768bps YoY (+430 bps QoQ) to 24.4%.

Laurus Labs Ltd. has an average target of 633.50 from 4 brokers.

Laurus Labs Ltd.

26 Apr 2025

620.55

2.77%

Laurus Labs Eyes 24% EBITDA Margin In FY26 After Strong Q4 Results

NDTV Profit

Laurus Labs clocked an EBITDA margin of 27.7% in Q4 FY25 as against 18% in the year-ago period.

Laurus Labs Ltd. is trading above all available SMAs

Laurus Labs Ltd.

25 Apr 2025

620.55

2.77%

Laurus Labs falls 6% despite strong Q4 results: Here's what brokerages say

Business Standard

Laurus Labs stock was quoting at 618.50, down 4.18 per cent from the previous session's closing price of 645.50

Laurus Labs Ltd. is trading above all available SMAs

Laurus Labs Q4 profit rises 3-fold to 234 cr; revenue at 1,440 cr

Business Line | 24 Apr 2025 2 more

Laurus Labs Ltd.

25 Apr 2025

620.55

2.77%

Laurus Labs (HOLD): Visibility of Operating Leverage

Hold: Laurus Labs Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Revenue/EBITDA/PAT exceeded our estimates by 8.4%/32.6%/110.3%; EBITDA margin surpassed our estimate by 440 bps

Laurus Labs Ltd. is trading above all available SMAs

Laurus Labs Ltd.

24 Apr 2025

620.55

2.77%

to see Rapid results content

Laurus Labs Ltd.

24 Apr 2025

620.55

2.77%

FDF/CDMO drives earnings; ends FY25 on strong note

Buy: Laurus Labs Ltd.

Target

Motilal Oswal

Laurus Lab (LAURUS) delivered a second consecutive quarter with betterthan-expected performance, led by healthy traction in the Formulation (FDF)/API segment. Despite softer-than-expected performance in the CDMO business during 4QFY25, the quarterly sales run rate continued its uptrend.

KRChoksey released a Accumulate report for Laurus Labs Ltd. with a price target of 687.0 on 30 Apr, 2025.

Laurus Labs Ltd.

11 Apr 2025

620.55

2.77%

Laurus Labs surges 8%, stock records sharpest intraday gain since Jan 30

Business Standard

The pipeline is expected to be robust, and the company expects to do well in the human health and animal health CDMO divisions in Q4FY25E and in FY26E, according to analysts.

Laurus Labs Ltd. is trading above all available SMAs

Laurus Labs Ltd.

04 Apr 2025, 12:13AM

620.55

2.77%

Laurus Labs to invest 5,000 crore in new manufacturing plant in Andhra Pradesh

Business Line

The State government will allot land for the proposed plant in Rambilli village, Anakapalli district

Laurus Labs Ltd. has an average target of 633.50 from 4 brokers.

Laurus Labs Ltd.

27 Jan 2025

620.55

2.77%

Laurus Labs shares down 15% on profit booking post Q3 earnings; Should you buy or sell?

livemint

Goldman Sachs has retained its Sell' rating on Laurus Labs, setting a price target of 475. The brokerage noted that although the management did not offer specific revenue guidance for FY2025.

Laurus Labs Ltd. has gained 24.16% in the last 6 Months

Laurus Labs Shares Hit Two-Month Low Amid US Foreign Aid Pause, ARV Sales Concerns

NDTV Profit | 27 Jan 2025 1 more

Laurus Labs Ltd.

27 Jan 2025

620.55

2.77%

Late stage projects and high value API to drive growth

Accumulate: Laurus Labs Ltd.

Target

KRChoksey

Laurus Labs’ revenue beat our estimates significantly due to strong growth in Custom Synthesis segment and FDF segment. EBITDA beat our estimates due to better-than-expected gross profit and Adj. PAT beat our estimates due to strong operating performance.